Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Explores AI Content Marketplace With Media Publishers 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
BRISBANE, Calif., June 26, 2017 -- KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it has been approved for trading its stock on the OTCQB® Venture Market, upgrading from the Pink Market®.
The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission. The OTCQB trading standards require that companies be current in their regulatory filings, complete an annual verification and management certification, and have a minimum $0.01 bid price.
“Trading on the OTCQB is another incremental step forward in our strategy to improve the financial foundation of KaloBios, enhance liquidity in our stock and continue to build more trust in the investment community,” said Cameron Durrant, MD, chairman and CEO of KaloBios. “Meantime, we will continue to pursue the key corporate goal of uplisting to a national securities exchange.”
Investors and all stakeholders can find more information about the OTCQB market, quotes and other details at www.otcmarkets.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
